555 related articles for article (PubMed ID: 31054983)
1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
[TBL] [Abstract][Full Text] [Related]
2. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Efebera YA; Qureshi SR; Cole SM; Saliba R; Pelosini M; Patel RM; Koca E; Mendoza FL; Wang M; Shah J; Alousi A; Hosing C; Popat U; Kebriaei P; Anderlini P; Khouri IF; Champlin R; Giralt S; Qazilbash MH
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1122-9. PubMed ID: 20178853
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].
Pan P; Wang JL; Zhai WH; Ma QL; Yang DL; Feng SZ; Han MZ; Pang AM; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):28-34. PubMed ID: 38527835
[No Abstract] [Full Text] [Related]
5. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Sahebi F; Garderet L; Kanate AS; Eikema DJ; Knelange NS; Alvelo OFD; Koc Y; Blaise D; Bashir Q; Moraleda JM; Dreger P; Sanchez JF; Ciurea S; Schouten H; Shah NN; Verbeek M; Rösler W; Diez-Martin JL; Schoenland S; D'Souza A; Kröger N; Hari P
Biol Blood Marrow Transplant; 2019 Feb; 25(2):335-342. PubMed ID: 30243581
[TBL] [Abstract][Full Text] [Related]
6. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
8. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
[TBL] [Abstract][Full Text] [Related]
11. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
[TBL] [Abstract][Full Text] [Related]
13. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
14. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.
Greil C; Engelhardt M; Ihorst G; Schoeller K; Bertz H; Marks R; Zeiser R; Duyster J; Einsele H; Finke J; Wäsch R
Haematologica; 2019 Feb; 104(2):370-379. PubMed ID: 30237266
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
17. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
19. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
20. Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello A; Bataller L; Piñana JL; Montoro J; Lorenzo I; Villalba A; Freiria C; Santiago M; Sevilla T; Muelas N; Guerreiro M; Carretero C; Gómez I; Solves P; Sanz MÁ; Sanz G; Sanz J
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1818-1824. PubMed ID: 31132454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
